{"url_path":"/sec/engnw/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270384-index.html","accession_number":"0001193125-26-270384","cik":"0001980845","ticker":"ENGN","issuer_name":"enGene Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270384-index.html","primary_entity_key":"0001980845","primary_entity_name":"enGene Therapeutics Inc."},"word_count":85,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n## (d) Exhibits\n\nExhibit No.\n\n \n\nDescription of Exhibits\n\n[99.1](engn-ex99_1.htm)\n\n \n\n[Press Release dated June 15, 2026](engn-ex99_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nENGENE THERAPEUTICS INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 15, 2026\n\nBy:\n\n/s/ Ronald H. W. Cooper\n\n \n\n \n\n \n\nName: Ronald H. W. Cooper\nTitle: Chief Executive Officer"}